Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: A randomized trial

• DOI: 10.1111/jgh.12791
• Publication Date: 2014-09-24T11:03:14Z
• Authors: Giovan Giuseppe D...; Raffaella Tortora; Giuseppe D'Adamo; Massimo De Luca; Filippo Lampasi; Luigi Addario; Alfonso Galeota L...; Francesco Paolo P...; Maria Teresa Tart...; Gabriella Cordone; Michele Imparato; Silvana Mattera; Claudio Maurizio ...
• Keywords: Milan criteria; Clinical endpoint

In patients with cirrhosis and small hepatocellular carcinoma (HCC), thermal ablation is currently recognized as an effective local treatment. Among procedures, radiofrequency (RFA) the most diffusely used standard against which any new treatment should be compared. retrospective studies, laser (LA) resulted safe RFA. Therefore, we performed a non-inferiority randomized trial comparing RFA LA in HCC within Milan criteria.Overall, 140 157 nodules were randomly assigned to receive or LA. The primary end-point was proportion of complete tumor (CTA). Secondary end-points time progression (TTLP) overall survival (OS).Per patient CTA rates after 97.4% (95% CI, 91.0-99.3) 95.7% (88.1-98.5), respectively (difference = 1.4%, 95% CI from -6.0% + 9.0%). Per nodule for (91.0-99.3) 96.3% (89.6-98.7), 1.1%, -5.7% 8.1%). mean TTLP comparable between group (42.0 months; 36.83-47.3) (46.7 41.5-51.9) (P .591). OS 42 months both groups probability at 1 3 years 94% 89% group, 80% group.LA not inferior inducing therefore it considered evaluable alternative cirrhotic patients.